ARMA (Antireflux Mucosa Ablation) in Patients With Chronic Refractory Reflux Disease

Launched by KLINIKUM GARMISCH-PATENKIRCHEN · Jun 15, 2022

Keywords

ClinConnect Summary

Prospective, non-controlled, monocentric pilot study in patients with therapy-refractory reflux symptoms under proton pump inhibitor (PPI) therapy or intolerance of the necessary therapy or rapid recurrence of the symptoms with tapering therapy.

The symptoms must have existed for \>6 months. Gastroesophageal reflux disease (GERD) must be diagnosed before inclusion in the study. This is the case if either erosive reflux esophagitis according to Los Angeles classification grades A-D is present or non-erosive reflux disease (NERD) has been confirmed by a 24-hour pH measurement/impedance measu...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • typical reflux symptoms more than 2x per week during PPI therapy more than 6 month
• • proof of gastro-esophageal reflux in pH metry oder pH/Impedance measurement
• Exclusion Criteria:
• • age \< 18 y
• • primary motility disorder of the esophagus
• • hiatal hernia \> 3 cm
• • Hill classification \> III
• • pregnancy
• • coagulation disorder
• • mandatory intake of oral anticoagulation drugs